New-Onset Treatment-Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder

Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD Study

(2009) Ling Zheng et al.   AMERICAN JOURNAL OF PSYCHIATRY

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?

(2009) Viktoria Simon et al.   JOURNAL OF CLINICAL PSYCHIATRY

Dyslipidemia Independent of Body Mass in Antipsychotic-Treated Patients Under Real-Life Conditions

(2009) Astrid B. Birkenaes et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Metabolic risks in older adults receiving second-generation antipsychotic medication

(2009) John O. Brooks et al.   Current Psychiatry Reports

Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study

(2008) Stewart G. Albert et al.   Journal of the American Medical Directors Association

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

(2008) Marc De Hert et al.   SCHIZOPHRENIA RESEARCH

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

(2008) Jonathan M. Meyer et al.   SCHIZOPHRENIA RESEARCH

Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database

(2007) Antoni Sicras-Mainar et al.   EUROPEAN PSYCHIATRY